Myasthenia Gravis – Competitive Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2021-2028

Myasthenia Gravis (MG) is the prototype neuromuscular disease with the immunological pathogenesis. It is an acquired autoimmune disease affecting synaptic transmission via the neuromuscular junction mainly due to the presence of autoantibodies against the acetylcholine receptors (AChR) between the synaptic space of the skeletal muscles. It leads to an impairment of the neuromuscular transmission and corresponding clinical symptoms such as fluctuating muscle weakness and fatigability.

GET FREE SAMPLE PDF : https://www.wiseguyreports.com/sample-request/5762581-myasthenia-gravis-competitive-analysis-2019

MG can be managed effectively with therapies that include anticholinesterase agents, rapid immunomodulatory therapies, chronic immunosuppressive agents, and thymectomy. Treatment is individualized and depends upon the age of the patient; the severity of the disease, particularly dictated by respiratory or bulbar involvement; and the pace of progression. The goals of therapy in MG are to render patients minimally symptomatic or better while minimizing side effects from medications. MG is a chronic but treatable disease, and many patients can achieve sustained remission of symptoms and full functional capacity.

REPORT DETAILS: https://www.wiseguyreports.com/reports/5762581-myasthenia-gravis-competitive-analysis-2019

Most patients need immunosuppression in addition to symptomatic therapy. Prednisolone and azathioprine represent first choice drugs, whereas several second-choice options are recommended and being considered. The marketed products for the treatment of Myasthenia Gravis include Eculizumab (Alexion Pharmaceuticals); Tacrolimus (Astellas Pharma) and Venoglobulin (Mitsubishi Tanabe Pharma Corporation).

ALSO READ: http://www.marketwatch.com/story/yogurt-drinks-market-research-report-with-size-share-value-cagr-outlook-analysis-latest-updates-data-and-news-2021-2028-2021-06-24

The pipeline development for the treatment of Myasthenia Gravis is robust with approximately 15+ active products in this area. The key players involved in the development of the therapeutics include Akari Therapeutics (Coversin), Alpha Cancer Technologies (ACT-101), AnTolRx (Pre-clinical Program), Argenx (Efgartigimod), Catalyst Pharmaceuticals (Amifampridine Phosphate), CSL Behring (Human normal immunoglobulin G (IgG)), CuraVac (Myasterix), Grifols Therapeutics (IGIV-C), GT Biopharma (GTP-004), Hibernaid (HBN-1 (IV); HBN-100), Immunovant (Roivant Sciences) (RVT-1401), Momenta Pharmaceuticals (M281), Novartis (Iscalimab), Protalex (PRTX-100), Ra Pharmaceuticals (Zilucoplan), Toleranzia (Myasthenia Gravis-Tolerogen), Tolerion (TOL 3034) and UCB Pharma (Rozanolixizumab).
Majority of the drugs under development are monoclonal antibody and small molecule. The development and launch of these therapies are expected to lead to the better treatment and longer life span of the individuals with Myasthenia Gravis.

ALSO READ: http://www.marketwatch.com/story/online-survey-software-market-research-report-with-size-share-value-cagr-outlook-analysis-latest-updates-data-and-news-2021-2028-2021-06-25

TABLE OF CONTENTS
1. REPORT INTRODUCTION
1.1 Objective of the Study 13
1.2 Secondary Research 13
1.3 Scope of the report: 13
2. DISEASE OVERVIEW 14
2.1 Introduction 14
2.2 Classification of MG 15
2.2.1 Congenital MG 15
2.2.2 Ocular MG 15
2.2.3 Generalized MG 15
2.2.4 Transient Neonatal MG 15

ALSO READ: http://www.marketwatch.com/story/bio-active-protein-market-research-report-with-size-share-value-cagr-outlook-analysis-latest-updates-data-and-news-2020-2026-2021-06-28

2.2.5 Juvenile MG 16
2.3 Clinical Classification 18
2.4 Signs and Symptoms 20
2.5 Causes 22
2.6 Pathogenesis 23
2.7 Pathophysiology 25
2.7.1 Presynaptic Surface 25
2.7.2 Synaptic Cleft 26
2.7.3 Postsynaptic Surface 27
2.7.4 The Acetylcholine Receptor 28
2.7.5 Neuromuscular Junction Formation and Muscle-Specific Kinase 29
2.7.6 Safety Factor for Neuromuscular Transmission 29
2.7.7 Immunopathology 30

….. continued

CONTACT DETAILS : 

[email protected]

+44 203 500 2763

+1 62 825 80070

971 0503084105

Source – HeraldKeeper
Note: The Heraldkeeper News Department was not involved in the creation of this content.

If you have any problem with this press release? Contact the source provider Heraldkeeper.com, you can contact them here.

Related Articles

Stay Connected

0FansLike
2,987FollowersFollow
0SubscribersSubscribe
- Advertisement -spot_img

Latest Articles